Blood · 2012
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vasmatzis George, Johnson Sarah H, Knudson Ryan A, Ketterling Rhett P, Braggio Esteban, Fonseca Rafael, Viswanatha David S, Law Mark E, Kip N Sertac, Ozsan Nazan, Grebe Stefan K, Frederick Lori A, Eckloff Bruce W, Thompson E Aubrey, Kadin Marshall E, Milosevic Dragana, Porcher Julie C, Asmann Yan W, Smith David I, Kovtun Irina V, Ansell Stephen M, Dogan Ahmet, Feldman Andrew L
Аннотация
Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only ∼ 35%. Improvement in outcomes has been stymied by poor understanding of the genetics and molecular pathogenesis of PTCL, with a resulting paucity of molecular targets for therapy. We developed bioinformatic tools to identify chromosomal rearrangements using genome-wide, next-generation sequencing analysis of mate-pair DNA libraries and applied these tools to 16 PTCL patient tissue samples and 6 PTCL cell lines. Thirteen recurrent abnormalities were identified, of which 5 involved p53-related genes (TP53, TP63, CDKN2A, WWOX, and ANKRD11). Among these abnormalities were novel TP63 rearrangements encoding fusion proteins homologous to ΔNp63, a dominant-negative p63 isoform that inhibits the p53 pathway. TP63 rearrangements were seen in 11 (5.8%) of 190 PTCLs and were associated with inferior overall survival; they also were detected in 2 (1.2%) of 164 diffuse large B-cell lymphomas. As TP53 mutations are rare in PTCL compared with other malignancies, our findings suggest that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL.
Предметные рубрики MeSH
Cell Line, TumorCyclin-Dependent Kinase Inhibitor p16DNA Mutational AnalysisFemaleGene RearrangementGenome-Wide Association StudyHumansLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, PeripheralMaleMutant ProteinsMutationOligonucleotide Array Sequence AnalysisOncogene Proteins, FusionOxidoreductasesRepressor ProteinsSequence Homology, Nucleic AcidTranscription FactorsTumor Suppressor Protein p53Tumor Suppressor ProteinsUnited StatesWW Domain-Containing Oxidoreductase